Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/278581
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19 |
Autor: | Alegría-Arcos, Melissa; Barbosa, Tábata; Sepúlveda, Felipe; Combariza, Germán; Gonzalez, Janneth; Gil, Carmen CSIC ORCID ; Martínez Gil, Ana CSIC ORCID ; Ramírez, David | Palabras clave: | COVID-19 SARS-CoV-2 Drug repurposing Network pharmacology Polypharmacology Protein–drug interaction network Protein–protein interaction network |
Fecha de publicación: | 17-ago-2022 | Editor: | Frontiers Media | Citación: | Frontiers in Pharmacology 13: 952192 (2022) | Resumen: | The coronavirus disease 2019 pandemic accelerated drug/vaccine development processes, integrating scientists all over the globe to create therapeutic alternatives against this virus. In this work, we have collected information regarding proteins from SARS-CoV-2 and humans and how these proteins interact. We have also collected information from public databases on protein-drug interactions. We represent this data as networks that allow us to gain insights into protein-protein interactions between both organisms. With the collected data, we have obtained statistical metrics of the networks. This data analysis has allowed us to find relevant information on which proteins and drugs are the most relevant from the network pharmacology perspective. This method not only allows us to focus on viral proteins as the main targets for COVID-19 but also reveals that some human proteins could be also important in drug repurposing campaigns. As a result of the analysis of the SARS-CoV-2-human interactome, we have identified some old drugs, such as disulfiram, auranofin, gefitinib, suloctidil, and bromhexine as potential therapies for the treatment of COVID-19 deciphering their potential complex mechanism of action. | Descripción: | 11 p.-4 fig.-1 tab. | Versión del editor: | https://doi.org/10.3389/fphar.2022.952192 | URI: | http://hdl.handle.net/10261/278581 | DOI: | 10.3389/fphar.2022.952192 | E-ISSN: | 1663-9812 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fphar_alegría-arcos_2022.pdf | Artículo principal | 2,71 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
6
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
6
checked on 24-feb-2024
Page view(s)
132
checked on 26-abr-2024
Download(s)
59
checked on 26-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons